Suven Pharmaceuticals Share Price

₹ 440.35

-₹6.70 (-1.5%)
1D
Last updated 03 Nov, 2026, 15:53 IST
NSE: COHANCE
|
Pharmaceuticals

Suven Pharmaceuticals Share Price Today

As of 4 Nov 2026, Suven Pharmaceuticals share price is ₹440.35. The stock opened at ₹450.00, compared to its previous close of ₹447.05. During today's trading session, Suven Pharmaceuticals share price moved in the range of ₹438.50 to ₹453.15, with an average price of ₹445.82 for the day. Looking at its last 52-week, the stock has touched a low of ₹266.70 and a high of ₹760.80.

Share price over the last 1 day fell from 448.75 to 440.05, ranging between 439.25 and 452.50.
₹438.50
1.50% down today
₹453.15
1D LOW
1D HIGH

Suven Pharmaceuticals Stock Insights

Latest Earning
Op Profit TrendDown by 315.32% QoQ
Latest Earning
Net Profit TrendDown by 643.80% QoQ
Latest Earning
Revenue TrendDown by 29.61% QoQ
Stock Performance
OutperformingBeat Nifty by 9.98 % in last 3 month
Shareholding Pattern
PromoterPromoter decreased stake by 0.01%
Shareholding Pattern
DIIDII increased stake by 2.36%
Shareholding Pattern
FIIFII increased stake by 18.61%
Technical Indicators
MACD CrossThe MACD line crossed below the signal line on 1 Day interval.
Suven Pharmaceuticals stock performance
Open₹450.00
High₹453.15
Low₹438.50
Prev. close₹447.05
Suven Pharmaceuticals trading activity
Volume3,30,046
Average traded price₹445.08
Last traded time03:53:25 03 Nov
Last traded quantity75
Circuit
L
H
₹357.65
₹536.45
52-week
L
H
₹266.70
₹760.80
Mkt Cap Cr
17,088.71
P/E
291.93
P/B
4.37
ROA
1.02%
ROE
5.05%
ROCE
5.47%
Quick Ratio
1.91
EV/EBITDA
53.04

Based on fundamentals, this stock's

Performance: 3 out of 5, Neutral
Performance
Neutral
Cohance Life performance is moderate compared to markets
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Cohance Life appears overvalued compared to its peers
Earnings: 1 out of 5, Very Poor
Earnings
Very Poor
Cohance Life revenue, operating profits and net profits have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,24,202.4238.614.759.61%13.79%18.65%2.3122.27
Divis Laboratories2,57,902.7390.3115.7614.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,74,402.4783.099.494.7%11.42%11.37%0.7533.6
Laurus Labs1,26,811.2895.1720.9211.58%22.11%20.91%0.6854.77
Zydus Lifesciences1,23,685.4926.934.568.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,11,868.0340.542.884.79%7.21%8.58%1.3519.05
Cipla1,11,647.7239.123.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,195.6245.155.817.82%12.76%14.68%0.7425.01
Aurobindo Pharma96,951.1826.132.566.34%9.25%11.76%1.1512.38
Lupin91,870.1616.454.0714.47%23.76%24.88%1.429.83

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Suven Pharmaceuticals Company Background

ISIN
INE03QK01018
Sector Market Cap
₹ 17,088.71 Cr

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.

Suven Pharmaceuticals Financial Highlights

  • Revenue: Suven Pharmaceuticals reported revenue of ₹2,302.64 crore in FY26 vs ₹2,677.71 crore in FY25. It showed a decrease of 14.01% on a yearly basis.
  • Operating Profit: Suven Pharmaceuticals reported an operating profit of ₹207.04 crore in FY26 vs ₹642.63 crore in FY25. It showed a decrease of 67.78% on a year-on-year basis.
  • Net Profit: Suven Pharmaceuticals reported a net profit of ₹150.12 crore in FY26 vs ₹484.24 crore in FY25. It showed a decrease of 69.00% on a yearly basis.

Suven Pharmaceuticals Quarterly Result Highlights

  • Suven Pharmaceuticals reported revenue of ₹434.51 crore in Jun 2026, compared with ₹617.28 crore in Mar 2026, representing a decrease of 29.61% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported an operating loss of ₹42.87 crore in Jun 2026, compared with ₹19.91 crore in Mar 2026, representing a decrease of 315.32% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported a loss of ₹45.19 crore in Jun 2026, compared with ₹8.31 crore in Mar 2026, reflecting a decrease of 643.80% on a QoQ basis.
  • The earnings per share (EPS) of Suven Pharmaceuticals stood at ₹4.69 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
57.48%
FII
7.71%
Other DII
1.93%
Retail and other
15.95%
Mutual funds
16.93%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20256.02%
Mar 20265.59%
Jun 20266.50%
Sep 20267.71%

Suven Pharmaceuticals Investment Returns

1 day
--
1 week
--
1 month
--
1 year
--
3 years
--
5 years
--

Suven Pharmaceuticals Share Price History

Suven Pharmaceuticals share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
03 Nov 26
₹450.00 / ₹440.35
-1.50%
02 Nov 26
₹446.00 / ₹447.05
+0.62%
30 Oct 26
₹478.00 / ₹444.30
-7.70%
29 Oct 26
₹476.20 / ₹481.35
+1.11%
Show more

Suven Pharmaceuticals Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,268.55₹2,608.50₹1,051.35₹1,340.33
Other Income₹34.09₹69.21₹61.91₹46.36
Total Revenue₹2,302.64₹2,677.71₹1,113.26₹1,386.69
Total Expenses₹2,066.13₹2,019.30₹707.59₹826.96
Profit Before Tax₹207.04₹642.63₹405.67₹559.73
Tax₹56.92₹158.39₹105.39₹148.44
Profit After Tax₹150.12₹484.24₹300.28₹411.29
EPS - Basic₹4.69₹12.79₹11.80₹16.16
EPS - Diluted₹4.68₹12.68₹11.80₹16.16

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹207.04₹642.63₹405.67₹559.73
Income before WC changes₹415.33₹849.99₹421.02₹597.19
Change in Assets₹7.92₹7.15₹70.44₹59.22
Change in Liabilities₹12.84-₹7.88-₹23.03-₹53.45
Change in WC₹20.76-₹0.73₹47.41₹5.77
Cash flow from Operations₹368.32₹673.35₹358.48₹457.20
Cash flow from Investing-₹254.57-₹389.70-₹362.25-₹195.01
Cash flow from Financing-₹165.15-₹327.40-₹13.80-₹241.95
Total Cash Flow-₹51.40-₹43.75-₹17.57₹20.24
Cash (Start of the year)₹96.65₹138.32₹64.80₹44.56
Cash (End of the year)₹49.14₹96.65₹47.23₹64.80

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,933.38₹3,722.79₹990.90₹954.70
Current Assets₹1,796.26₹1,758.17₹1,263.19₹1,011.05
Total Assets₹5,729.64₹5,480.96₹2,254.09₹1,965.74
Current Liabilities₹645.93₹705.41₹106.90₹158.77
Net Current Asset₹1,150.33₹1,052.76₹1,156.29₹852.28
Non-Current Liabilities₹1,049.88₹982.67₹96.53₹71.79
Equity Capital₹4,033.83₹3,792.88₹2,050.66₹1,735.18
Total Equity & Liabilities₹5,729.64₹5,480.96₹2,254.09₹1,965.74

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,030.50₹2,504.43₹1,051.35₹1,330.08
Other Income₹44.73₹64.84₹56.61₹44.55
Total Revenue₹2,075.23₹2,569.27₹1,107.96₹1,374.63
Total Expenses₹1,732.13₹1,903.43₹707.54₹795.24
Profit Before Tax₹313.63₹650.06₹400.42₹579.39
Tax₹84.92₹158.88₹103.95₹146.79
Profit After Tax₹228.71₹491.18₹296.47₹432.60
EPS - Basic₹5.98₹12.89₹11.65₹16.99
EPS - Diluted₹5.97₹12.80₹11.65₹16.99

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹313.63₹650.06₹400.42₹579.39
Income before WC changes₹426.55₹838.83₹417.56₹615.08
Change in Assets₹27.45₹11.17₹90.72₹79.68
Change in Liabilities₹2.65₹9.08-₹23.56-₹56.15
Change in WC₹30.10₹20.25₹67.16₹23.53
Cash flow from Operations₹389.57₹686.23₹376.20₹492.82
Cash flow from Investing-₹204.29-₹455.35-₹362.40-₹236.86
Cash flow from Financing-₹202.78-₹309.91-₹39.99-₹243.14
Total Cash Flow-₹17.50-₹79.03-₹26.19₹12.81
Cash (Start of the year)₹30.61₹109.55₹44.65₹30.21
Cash (End of the year)₹13.11₹30.61₹18.46₹43.02

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,444.53₹3,423.54₹990.65₹1,003.21
Current Assets₹1,668.67₹1,613.51₹1,224.23₹955.12
Total Assets₹5,113.20₹5,037.05₹2,214.88₹1,958.33
Current Liabilities₹504.71₹553.78₹117.15₹154.18
Net Current Asset₹1,163.96₹1,059.73₹1,107.08₹800.94
Non-Current Liabilities₹128.38₹215.50₹69.38₹54.77
Equity Capital₹4,480.11₹4,267.77₹2,028.35₹1,749.38
Total Equity & Liabilities₹5,113.20₹5,037.05₹2,214.88₹1,958.33
* All values are in INR Crore
Suven Pharmaceuticals market depth
Bid quantityBid priceAsk priceAsk quantity
83440.3500
0000
0000
0000
0000
Total bid quantity83
Total ask quantity0
Suven Pharmaceuticals technical summary
Bearish indicators0
Neutral indicators4
Bullish indicators4
OverallSlightly Bullish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
46.28
Neutral
ATR (14)
18.45
Neutral
STOCH(9,6)
18.15
Bullish
STOCH RSI (14)
11.61
Bullish
ADX(9)
17.72
Bullish
UO(9)
48.38
Neutral
ROC(12)
0.33
Bullish
WillR(14)
-70.18
Neutral
Period
Simple value
Exponential vaue
5D
465.6
457.85
10D
461.48
459.32
20D
455.44
457.22
50D
453.17
452.09
100D
445.77
439.68
Volume trend — traded volume by day
3 Nov3L
2 Nov4L
30 Oct14L
29 Oct14L
28 Oct6L
Average8L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Suven Pharmaceuticals
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Suven Pharmaceuticals

Fund name
AUM
DSP Healthcare Fund
3.04%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
2.77%
UTI Healthcare Fund
2.66%

Suven Pharmaceuticals Returns Calculator

Suven Pharmaceuticals Latest News

2 months ago
MMTC, Emmvee Photovoltaic, Acme Solar shares surge amid heavy volumes; check full list
2 months ago
Navin Fluorine, Cohance Lifesciences, Neuland Labs shares surge amid spike in trading activity
4 months ago
Cohance Lifesciences, Piramal Pharma, Kirloskar Oil shares surge amid heavy volumes; check full list
Showing news item 1 of 3

Top Gainers

KRBL Share Price
₹401.45
+38.45 (+10.59%)
MARICO Share Price
₹878.40
+79.85 (+10%)
BALRAMCHIN Share Price
₹654.80
+54.9 (+9.15%)
TRIDENT Share Price
₹23.79
+1.58 (+7.11%)
AEGISLOG Share Price
₹1177.10
+77 (+7%)
See more

Top Losers

KEC Share Price
₹316.35
-32.65 (-9.36%)
GNFC Share Price
₹465.05
-45.95 (-8.99%)
PRAJIND Share Price
₹254.63
-16.5 (-6.09%)
AIAENG Share Price
₹3389.70
-217.6 (-6.03%)
GESHIP Share Price
₹1536.50
-63.9 (-3.99%)
See more

Suven Pharmaceuticals Share Price FAQs

Please be aware that Suven Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.